アミノ酸代謝異常症治療のグローバル市場(2020~2030):フェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症

■ 英語タイトル:Amino acid Metabolism Disorders Treatment Market By Indication (Phenylketonuria, Maple syrup urine disease, Citrullinemia, Homocystinuria, Argininosuccinic aciduria), By Product (Folic Acid, Vitamin B6 and B12, Arginine, Thiamine, Betaine, Sapropterin, Others), By Distribution channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート(データ管理コード:ALD23JN079)■ 発行会社/調査会社:Allied Market Research
■ 商品コード:ALD23JN079
■ 発行日:2022年9月
■ 調査対象地域:グローバル
■ 産業分野:生命科学
■ ページ数:350
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Online Only(1名閲覧、印刷不可)USD3,570 ⇒換算¥542,640見積依頼/購入/質問フォーム
Single User(1名閲覧)USD5,730 ⇒換算¥870,960見積依頼/購入/質問フォーム
Enterprise User(閲覧人数無制限)USD9,600 ⇒換算¥1,459,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[アミノ酸代謝異常症治療のグローバル市場(2020~2030):フェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Allied Market Research社の本レポートでは、2021年に630.92百万ドルであった世界のアミノ酸代謝異常症治療市場規模が2031年には961.75百万ドルに達し、2022年から2031年にかけて年平均4.3%成長すると予測しています。Allied Market Research社の本レポートでは、世界のアミノ酸代謝異常症治療市場について幅広く調査し、イントロダクション、エグゼクティブサマリー、市場概要、疾患別分析(フェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症)、製品別分析(葉酸、ビタミンB6&B12、アルギニン、チアミン、その他)、流通経路別分析(病院薬局、ドラッグストア&小売薬局、オンラインプロバイダー)、地域別分析(北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ)、企業状況、企業情報など、以下の内容を掲載しています。さらに、AMINO GmbH、Civentichem, LLC, Ltd.、GlaxoSmithKline PLC、Koninklijke DSM N.V.、Kyowa Hakko Kirin Co., Ltd.、Merck KGaA、Pfizer, Inc.、Recordati S.p.A.、Sanofi、Shine Star (Hubei) Biological Engineering Co.、BioMarin Pharmaceutical Inc.、Teva Pharmaceutical Industries Ltd.などの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のアミノ酸代謝異常症治療市場規模:疾患別分析
- フェニルケトン尿症における市場規模
- メープルシロップ尿症における市場規模
- シトルリン血症における市場規模
- ホモシスチン尿症における市場規模
- アルギニノコハク酸尿症における市場規模
・世界のアミノ酸代謝異常症治療市場規模:製品別分析
- 葉酸の市場規模
- ビタミンB6&B12の市場規模
- アルギニンの市場規模
- チアミンの市場規模
- その他製品の市場規模
・世界のアミノ酸代謝異常症治療市場規模:流通経路別分析
- 病院薬局チャネルの市場規模
- ドラッグストア&小売薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界のアミノ酸代謝異常症治療市場規模:地域別分析
- 北米のアミノ酸代謝異常症治療市場規模
- ヨーロッパのアミノ酸代謝異常症治療市場規模
- アジア太平洋のアミノ酸代謝異常症治療市場規模
- 中南米/中東・アフリカのアミノ酸代謝異常症治療市場規模
・企業状況
・企業情報

世界のアミノ酸代謝異常症治療市場は、2021年に6億3,092万ドルと評価され、2022年から2031年まで年平均成長率4.3%で成長して2031年には9億6,175万ドルに達すると予測されています。
代謝とは、複雑なタンパク質や炭水化物が体の燃料となる糖と酸に分解されるプロセスのことです。代謝過程に異常が生じると、代謝障害が起こります。その一つがアミノ酸代謝異常症です。アミノ酸は体の「構成要素」とも呼ばれます。アミノ酸代謝異常症は、アミノ酸の合成と分解の障害が原因で発生します。これらの問題は、生命を脅かす、健康上の問題を引き起こす体内の有害物質や有毒物質の蓄積につながります。アミノ酸代謝異常症のグループには、メープルシロップ尿症、フェニルケトン尿症、ホモシスチン尿症、シトルリン血症が含まれます。さらに、アミノ酸代謝異常症の治療には、ビタミンのサプリメント、薬、特別食が含まれます。

アミノ酸代謝異常症治療市場の成長は、主にメープルシロップ尿症、フェニルケトン尿症、シトルリン血症などのアミノ酸代謝異常症の有病率の増加によって駆動される治療法の高コスト、アミノ酸代謝異常症治療に関する研究開発活動の上昇、発展途上国における可処分所得の増加と医療インフラの開発。しかし、アミノ酸サプリメントのコストの増加、フェニルケトン尿症注射のアミノ酸代謝異常症と関連する副作用の認識の欠如は、市場の成長に影響を与えます。逆に、医療費の増加は、市場に有利な機会を提供します。

アミノ酸代謝異常症治療市場は、製品タイプ、疾患、流通チャネル、地域に区分されます。
製品タイプ別では、市場は葉酸、ビタミンB6・B12、アルギニン、チアミン、ベタイン、サプロプテリン、その他に分類されます。
疾患別では、市場はフェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症に分類されます。
流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。ドラッグストアや小売薬局のセグメントはさらに医療用医薬品とOTC医薬品に細分化されます。
地域別では、北米(米国、カナダ、メキシコ)、欧州(ドイツ、フランス、英国、イタリア、スペイン、その他欧州)、アジア太平洋(日本、中国、オーストラリア、インド、韓国、その他アジア太平洋)、LAMEA(ブラジル、サウジアラビア、南アフリカ、その他LAMEA)に市場を分けて分析しています。

世界のアミノ酸代謝異常症治療市場で事業を展開する主な主要企業は、Amino GmbH、Biogen Idec、Biomarin Pharmaceuticals, Inc.、GlaxoSmithKline Plc、Koninklijke DSM N.V.、Merck KGaA、Pfizer, Inc.、Pharmavite、Recordati S.p.A.、Sanofi、Shine Star (Hubei) Biological Engineering Co.などです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのアミノ酸代謝異常症治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、アミノ酸代謝異常症治療市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・アミノ酸代謝異常治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のアミノ酸代謝異常治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
疾患別
フェニルケトン尿症
メープルシロップ尿症
シトルリン血症
ホモシスチン尿症
アルギニノコハク酸尿症

製品別
葉酸
ビタミンB6・B12
アルギニン
チアミン
ベタイン
サプロプテリン
その他

流通チャネル別
病院薬局
ドラッグストア・薬局
処方箋種類
医療用医薬品
一般用医薬品
オンラインプロバイダー

地域別
・北米
カナダ
メキシコ
アメリカ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
AMINO GmbH
Civentichem, LLC, Ltd.
GlaxoSmithKline PLC
Koninklijke DSM N.V.
協和発酵バイオ株式会社(キリングループ)
Merck KGaA
Pfizer, Inc.
Recordati S.p.A.
Sanofi
Shine Star (Hubei) Biological Engineering Co.
BioMarin Pharmaceutical Inc.
Teva Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Phenylketonuria
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Maple syrup urine disease
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Citrullinemia
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Homocystinuria
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Argininosuccinic aciduria
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Folic Acid
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Vitamin B6 and B12
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Arginine
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Thiamine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Betaine
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Sapropterin
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Others
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
CHAPTER 6: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
6.3.4.1 Prescription drug Market size and forecast, by region
6.3.4.2 OTC drug Market size and forecast, by region
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Indication
7.2.3 North America Market size and forecast, by Product
7.2.4 North America Market size and forecast, by Distribution channel
7.2.4.1 North America Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Indication
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Indication
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Indication
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Indication
7.3.3 Europe Market size and forecast, by Product
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.4.1 Europe Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Indication
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Indication
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Indication
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Indication
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Indication
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Indication
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Indication
7.4.3 Asia-Pacific Market size and forecast, by Product
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.4.1 Asia-Pacific Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Indication
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Indication
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Distribution channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Indication
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Distribution channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Indication
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Indication
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Indication
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Indication
7.5.3 LAMEA Market size and forecast, by Product
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.4.1 LAMEA Drug Stores and Retail Pharmacies Amino acid Metabolism Disorders Treatment Market by Prescription type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Indication
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Indication
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Indication
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Indication
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AMINO GmbH
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Civentichem, LLC, Ltd.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 GlaxoSmithKline PLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Koninklijke DSM N.V.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Kyowa Hakko Kirin Co., Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck KGaA
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Recordati S.p.A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Shine Star (Hubei) Biological Engineering Co.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 BioMarin Pharmaceutical Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Teva Pharmaceutical Industries Ltd.
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 2. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PHENYLKETONURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 3. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR PHENYLKETONURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR MAPLE SYRUP URINE DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 5. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR MAPLE SYRUP URINE DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR CITRULLINEMIA, BY REGION, 2021-2031 ($MILLION)
TABLE 7. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR CITRULLINEMIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOMOCYSTINURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 9. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOMOCYSTINURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININOSUCCINIC ACIDURIA, BY REGION, 2021-2031 ($MILLION)
TABLE 11. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININOSUCCINIC ACIDURIA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 13. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR FOLIC ACID, BY REGION, 2021-2031 ($MILLION)
TABLE 14. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR FOLIC ACID, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR VITAMIN B6 AND B12, BY REGION, 2021-2031 ($MILLION)
TABLE 16. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR VITAMIN B6 AND B12, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ARGININE, BY REGION, 2021-2031 ($MILLION)
TABLE 18. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ARGININE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR THIAMINE, BY REGION, 2021-2031 ($MILLION)
TABLE 20. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR THIAMINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR BETAINE, BY REGION, 2021-2031 ($MILLION)
TABLE 22. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR BETAINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR SAPROPTERIN, BY REGION, 2021-2031 ($MILLION)
TABLE 24. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR SAPROPTERIN, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 26. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 28. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 29. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 31. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. GLOBAL DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 33. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR PRESCRIPTION DRUG, BY REGION, 2021-2031 ($MILLION)
TABLE 34. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR OTC DRUG, BY REGION, 2021-2031 ($MILLION)
TABLE 35. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 36. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 39. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 40. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. NORTH AMERICA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 42. NORTH AMERICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 44. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 45. U.S. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 47. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 48. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 50. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 51. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 53. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 54. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. EUROPE DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 56. EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 57. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 58. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 59. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 60. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 61. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 62. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 64. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 65. UK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 67. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 68. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 70. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 71. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 73. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 74. REST OF EUROPE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 76. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 77. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. ASIA-PACIFIC DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 79. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 80. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 81. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 82. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 84. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 85. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 87. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 88. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 90. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 91. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 92. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 93. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 94. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 99. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 100. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. LAMEA DRUG STORES AND RETAIL PHARMACIES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 102. LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 103. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 104. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 105. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 106. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 107. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 108. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 109. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 110. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 111. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 112. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 113. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 114. REST OF LAMEA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 115.AMINO GMBH: COMPANY SNAPSHOT
TABLE 116.AMINO GMBH: OPERATING SEGMENTS
TABLE 117.AMINO GMBH: PRODUCT PORTFOLIO
TABLE 118.AMINO GMBH: NET SALES,
TABLE 119.AMINO GMBH: KEY STRATERGIES
TABLE 120.CIVENTICHEM, LLC, LTD.: COMPANY SNAPSHOT
TABLE 121.CIVENTICHEM, LLC, LTD.: OPERATING SEGMENTS
TABLE 122.CIVENTICHEM, LLC, LTD.: PRODUCT PORTFOLIO
TABLE 123.CIVENTICHEM, LLC, LTD.: NET SALES,
TABLE 124.CIVENTICHEM, LLC, LTD.: KEY STRATERGIES
TABLE 125.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 126.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 127.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 128.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 129.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 130.KONINKLIJKE DSM N.V.: COMPANY SNAPSHOT
TABLE 131.KONINKLIJKE DSM N.V.: OPERATING SEGMENTS
TABLE 132.KONINKLIJKE DSM N.V.: PRODUCT PORTFOLIO
TABLE 133.KONINKLIJKE DSM N.V.: NET SALES,
TABLE 134.KONINKLIJKE DSM N.V.: KEY STRATERGIES
TABLE 135.KYOWA HAKKO KIRIN CO., LTD.: COMPANY SNAPSHOT
TABLE 136.KYOWA HAKKO KIRIN CO., LTD.: OPERATING SEGMENTS
TABLE 137.KYOWA HAKKO KIRIN CO., LTD.: PRODUCT PORTFOLIO
TABLE 138.KYOWA HAKKO KIRIN CO., LTD.: NET SALES,
TABLE 139.KYOWA HAKKO KIRIN CO., LTD.: KEY STRATERGIES
TABLE 140.MERCK KGAA: COMPANY SNAPSHOT
TABLE 141.MERCK KGAA: OPERATING SEGMENTS
TABLE 142.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 143.MERCK KGAA: NET SALES,
TABLE 144.MERCK KGAA: KEY STRATERGIES
TABLE 145.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 146.PFIZER, INC.: OPERATING SEGMENTS
TABLE 147.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 148.PFIZER, INC.: NET SALES,
TABLE 149.PFIZER, INC.: KEY STRATERGIES
TABLE 150.RECORDATI S.P.A.: COMPANY SNAPSHOT
TABLE 151.RECORDATI S.P.A.: OPERATING SEGMENTS
TABLE 152.RECORDATI S.P.A.: PRODUCT PORTFOLIO
TABLE 153.RECORDATI S.P.A.: NET SALES,
TABLE 154.RECORDATI S.P.A.: KEY STRATERGIES
TABLE 155.SANOFI: COMPANY SNAPSHOT
TABLE 156.SANOFI: OPERATING SEGMENTS
TABLE 157.SANOFI: PRODUCT PORTFOLIO
TABLE 158.SANOFI: NET SALES,
TABLE 159.SANOFI: KEY STRATERGIES
TABLE 160.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: COMPANY SNAPSHOT
TABLE 161.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: OPERATING SEGMENTS
TABLE 162.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: PRODUCT PORTFOLIO
TABLE 163.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: NET SALES,
TABLE 164.SHINE STAR (HUBEI) BIOLOGICAL ENGINEERING CO.: KEY STRATERGIES
TABLE 165.BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT
TABLE 166.BIOMARIN PHARMACEUTICAL INC.: OPERATING SEGMENTS
TABLE 167.BIOMARIN PHARMACEUTICAL INC.: PRODUCT PORTFOLIO
TABLE 168.BIOMARIN PHARMACEUTICAL INC.: NET SALES,
TABLE 169.BIOMARIN PHARMACEUTICAL INC.: KEY STRATERGIES
TABLE 170.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 171.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 172.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 173.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 174.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(ALD23JN079 )"アミノ酸代謝異常症治療のグローバル市場(2020~2030):フェニルケトン尿症、メープルシロップ尿症、シトルリン血症、ホモシスチン尿症、アルギニノコハク酸尿症" (英文:Amino acid Metabolism Disorders Treatment Market By Indication (Phenylketonuria, Maple syrup urine disease, Citrullinemia, Homocystinuria, Argininosuccinic aciduria), By Product (Folic Acid, Vitamin B6 and B12, Arginine, Thiamine, Betaine, Sapropterin, Others), By Distribution channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。